Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 2/20 | 0.30 |
| ▸ | ARG2 | P78540 | 2/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889871 | 1.00 | DPP4 (0.52) | DPP4SLC7A5FAPDPP8DPP9 | |
| SCHEMBL1953318 | 1.00 | DPP4 (0.52) | DPP4SLC7A5FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL14779945 | 0.97 | DPP4 (0.50) | DPP4SLC7A5FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL1953291 | 0.97 | DPP4 (0.50) | DPP4SLC7A5FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3220896 | 0.97 | DPP4 (0.50) | DPP4SLC7A5FAPDPP8DPP9 | |
| SCHEMBL13374234 | 0.81 | DPP4 (0.36) | DPP4SLC7A5DPP7ALDH1A1TSHR | |
| SCHEMBL4139897 | 0.81 | DPP4 (0.36) | DPP4SLC7A5DPP7ALDH1A1TSHR | |
| SCHEMBL4155785 | 0.81 | DPP4 (0.36) | DPP4SLC7A5DPP7ALDH1A1TSHR | |
| SCHEMBL3983698 | 0.81 | DPP4 (0.36) | DPP4SLC7A5DPP7ALDH1A1TSHR | |
| SCHEMBL4157374 | 0.81 | DPP4 (0.36) | DPP4SLC7A5DPP7ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | claimed |
| EP-0521666-B1 | Ampholyte terpolymers providing superior conditioning properties in shampoos and other hair care products | CALGON CORP (US) | 1997-12-10 | — | — | EP | claimed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220031858-A1 | NOVEL LINKERS | BICYCLETX LIMITED (GB) | 2022-02-03 | — | — | US | disclosed |
| US-10968183-B2 | Small molecule FIEL1 inhibitor in inflammatory and fibrotic lung injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3638669-A1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2020-04-22 | — | — | EP | disclosed |
| US-10344003-B2 | Small molecule FIEL1 inhibitor in inflammatory and fibrotic lung injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2898085-B1 | CELL LINES | MEDIMMUNE LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| WO-2018228920-A1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-20 | — | — | WO | disclosed |
| US-20180141916-A1 | NOVEL SMALL MOLECULE FIEL1 INHIBITOR IN INFLAMMATORY AND FIBROTIC LUNG INJURY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-24 | — | — | US | disclosed |
| US-6211235-B1 | ALZHEIMERS DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6207710-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6191166-B1 | ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| US-6096782-A | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942923-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998022493-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344003-B2 | Small molecule FIEL1 inhibitor in inflammatory and fibrotic lung injury | FIP1L1, TRIM28, TFPI2 | DPP4 2423/4885SLC7A5 3042/4885FAP 307/4885 |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | DPP4 2261/4885SLC7A5 2289/4885FAP 947/4885 |
| US-20180141916-A1 | NOVEL SMALL MOLECULE FIEL1 INHIBITOR IN INFLAMMATORY AND FIBROTIC LUNG INJURY | FIP1L1, TRIM28, TFPI2 | DPP4 2632/4885SLC7A5 3282/4885FAP 488/4885 |
| US-20220031858-A1 | NOVEL LINKERS | CD44, FOLH1, HACD3 | DPP4 1609/4885SLC7A5 19/4885FAP 1297/4885 |
| US-10968183-B2 | Small molecule FIEL1 inhibitor in inflammatory and fibrotic lung injury | FIP1L1, TRIM28, TFPI2 | DPP4 2423/4885SLC7A5 3042/4885FAP 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.